الفهرس 
The effect of direct antiviral agents (DAAs) on extra- hepatic manifestations in chronic hepatitis (C)
AbstractOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Introduction Management of extra-hepatic manifestations (EHMs) of HCV with direct-acting antiviral agents (DAAs) is focused on viral eradication and clinical remission. Data concerning the clinical and immunologic outcomes of DAAs in HCV-related EHMs is scarce. Aim: To assess the safety and efficacy (clinical and virologic response) of different sofosbuvir (SOF)-based regimens in a cohort of chronic HCV patients with different extra-hepatic manifestations. Methods One hundred adult chronic HCV patients with different EHMs were recruited from Endemic Medicine Department, Cairo University, Gastroenterology and Hepatology Department, El-Agouza Police Hospital and The National Hepatology and Tropical Medicine Research Institute (NHTMRI), Egypt. Different SOF-based regimens were used; group A (SOF-based DAAs combination, for 3 months, n=35); group B (INF-free therapy with SOF plus (ribavirin) RBV for 6 months, n=23) and group C (Pegylated-IFN/RBV plus SOF for 3 months, n=42). SVR 12; defined as negative HCV RNA at least 12 weeks after end of therapy and clinical response (partial response, PR complete response, CR)of EHMs were assessed.Results Overall SVR12 was 93% and CR was 89% in all studied groups and circulating cryoglobulins were significantly decreased with SVR12, p value 0.003. Both SVR12 and CR were significantly observed with IFN-free regimen p value, 0.004 rather than IFN-based, p value, 0.21